Development of live recombinant vaccine candidates against tuberculosis.
We report on 2 recombinant (r) live vaccine candidates that use different strategies to improve cell-mediated immunity for TB control: (i) the current TB vaccine strain Mycobacterium bovis BCG, endowed with a pore-forming cytolysin; and (ii) rSalmonella typhimurium secreting a single immunodominant antigen shared by BCG and M. tuberculosis.
Hess
J
J
Max-Planck-Institute for Infection Biology, Department of Immunology, Berlin, Germany.
Kaufmann
S H
SH
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D051379:Mice; D009163:Mycobacterium bovis / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000276:immunology; D012486:Salmonella typhimurium / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology* / Q000517:prevention & control; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D001500:BCG Vaccine; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic